Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls

McDonald's faces a class-action lawsuit alleging its AI-driven pricing tool enables anticompetitive practices, leading to supracompetitive prices. The plaintiff claims the tool, developed using data from Dynamic Yield, pressures franchisees to set prices based on pooled data, violating antitrust laws. McDonald's maintains franchisees set prices independently. The case is filed in the Northern District of Illinois (No. 1:26-cv-12149).

Union Pacific (UP) reports that shippers accounting for over 30% of its volume publicly support its proposed merger with Norfolk Southern (NS). UP's marketing chief notes that many other customers are quietly evaluating the deal. Opponents, including trade associations, argue the merger will raise rates and reduce options. Over 500 of UP's 10,000 customers have expressed support, while 800+ parties plan to participate in the merger proceedings.

A U.S. class-action lawsuit claims Starbucks falsely advertised eight protein drinks as 'sugar-free,' alleging they contain 13-21g of sugar per venti serving due to lactose. Starbucks denies the claims, stating it provides clear nutritional information. The lawsuit seeks damages and a trial by jury. Starbucks launched the drinks in 2025, targeting consumers seeking protein.

Coca-Cola (KO) is launching a prebiotic fiber-infused soda in a pilot program. Chipotle (CMG) is reportedly exploring takeover options, with speculation about a potential tie-up with Starbucks (SBUX). Constellation Brands (STZ) beat earnings expectations, with beer sales up 5%, but Modelo Especial and Corona Extra sales declined. The company acquired Spiked for up to $353 million.

Starbucks faces a class-action lawsuit for allegedly misleading consumers by labeling eight protein drinks as 'sugar-free' despite containing lactose. Plaintiffs claim the drinks have 13-21g of sugar, exceeding FDA limits. Starbucks denies wrongdoing and plans to defend itself.

Rocket Pharmaceuticals (RCKT) announced a clear plan for its phase 2 trial of RP-A501 for Danon disease, involving 12 male patients and focusing on myocardial LAMP2 protein expression.